Every material Form 8-K The Vita Coco filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vita Coco reported third-quarter 2025 results on October 29, 2025, with net sales up 37% to $182 million and net income of $24 million, or $0.40 per diluted share, compared with $19 million and $0.32 a year earlier. The company raised its full-year 2025 net sales guidance to $580 million to $595 million and its adjusted EBITDA guidance to $90 million to $95 million, although gross margin fell to 38% from 39%.
Q3 net sales were $182 million, up 37%, with Vita Coco Coconut Water net sales up 42%.
Q3 net income was $24 million ($0.40 diluted EPS) versus $19 million ($0.32); adjusted EBITDA was $32 million versus $23 million.
Full-year 2025 guidance: net sales of $580 million to $595 million and adjusted EBITDA of $90 million to $95 million.
Gross margin was 38% versus 39%, reflecting higher finished goods and tariff costs; the company reported no debt and $204 million in cash as of September 30, 2025.
Vita Coco reported second quarter 2025 net sales of $169 million, up 17% from a year earlier, and net income of $23 million, or $0.38 per diluted share, compared with $0.32 a year earlier. The company raised its full year 2025 net sales outlook to $565 million to $580 million, but gross margin fell to 36% from 41% and Non-GAAP Adjusted EBITDA declined to $29.2 million from $32.2 million.
Q2 2025 net sales rose 17% to $169 million; Vita Coco Coconut Water net sales grew 25%.
Net income was $23 million, or $0.38 per diluted share, versus $19 million, or $0.32, in Q2 2024.
Gross margin was 36% versus 41%; Non-GAAP Adjusted EBITDA was $29.2 million versus $32.2 million.
Full year 2025 net sales are now expected at $565 million to $580 million; Adjusted EBITDA at $86 million to $92 million.
Vita Coco's subsidiary signed a third amendment with supplier Century Pacific Agricultural Ventures, extending their manufacturing and purchasing agreement by five years to December 31, 2030. The amendment also changes pricing, annual volume and minimum volume commitments, which the filing does not quantify.
Agreement signed June 12, 2025 by All Market Singapore PTE Ltd. with Century Pacific Agricultural Ventures, Inc.
Term extended five years, to December 31, 2030, from the original September 17, 2012 agreement.
Amendment changes price, annual volume and minimum volume commitments; filing gives no figures.
Full text to be filed with the Form 10-Q for the quarter ending June 30, 2025.
Vita Coco reported first-quarter 2025 net sales up 17% to $131 million and net income of $19 million, up from $14 million a year earlier, with diluted EPS of $0.31 versus $0.24. Gross margin fell to 37% from 42%, and the company reaffirmed its full-year 2025 outlook, including net sales of $555 million to $570 million.
Net sales rose 17% to $131 million from $112 million; Vita Coco Coconut Water net sales grew 25%.
Gross margin declined to 37% from 42%, which the company attributed to higher ocean freight rates and finished goods costs.
Full-year 2025 outlook reaffirmed: net sales of $555 million to $570 million and adjusted EBITDA of $86 million to $92 million.
On April 28, 2025, the board raised the share repurchase authorization by $25.0 million to $65.0 million; about $42.1 million remained as of April 29, 2025.
Vita Coco reported fourth-quarter and full-year 2024 results, with net sales up 5% for the year to $516 million and net income up to $56 million. The company guided 2025 net sales to $555-570 million and Adjusted EBITDA to $86-92 million, which points to continued growth if met, though fourth-quarter net income fell from the prior year.
Q4 2024 net sales rose 20% to $127 million, but Q4 net income fell to $3 million ($0.06 per diluted share) from $7 million ($0.11).
Full-year 2024 net income rose to $56 million ($0.94 per diluted share) from $47 million ($0.79), and Adjusted EBITDA rose to $84 million from $68 million.
2025 outlook: net sales of $555-570 million, gross margin of 35-37%, and Adjusted EBITDA of $86-92 million; the outlook excludes any impact from potential tariffs.
Cash and cash equivalents were $165 million at December 31, 2024, with no debt outstanding.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every The Vita Coco filing is on SEC EDGAR ↗. 8-K briefs of other companies →